Freenome completed their SPAC on July 20, 2026 to list on NASDAQ with ticker FRNM with an implied valuation of $1.1B. Forge no longer actively tracks this company.
Freenome is a biotechnology company driven to provide the tools needed to detect, treat and prevent cancer using routing blood draw. This company was founded in 2014 by Gabe Otte, Riley Ennis, Charles Roberts and is headquartered in South San Francisco, CA. Freenome combines molecular biology with advanced computational biology and machine learning to help with early cancer detection.
You may invest in Freenome as it is a public company listed on the NASDAQ with ticker FRNM. But if you are an accredited investor interested in buying pre-IPO shares of a private company, you can learn more about how to invest in the private market or register today to get started.
Can you sell shares of Freenome before it goes public?
You can no longer sell shares of Freenome on Forge as this company is no longer private. However, if you own shares of a private company, Forge may be able to help you sell them in a way that works for you and the company. Learn more or register with us today to get started.
What is the pre-IPO value of my Freenome shares?
Forge can no longer determine the value of Freenome shares as this company is no longer private. However, if you own shares of a private company, Forge may help you value and sell them in a way that works for you and the company. Learn more or register with us today to get started.
Is Freenome a publicly traded company?
Freenome became a public company following its SPAC on 07/20/2026 and is now traded on the NASDAQ under the ticker FRNM.
To learn more about Freenome potential IPO
Will Freenome go IPO?
Freenome became a public company following its SPAC on 07/20/2026 and is now traded on the NASDAQ under the ticker FRNM.
What is Freenome’s IPO price?
The IPO price of Freenome is not currently available.
When was Freenome founded?
Freenome was founded in 2014.
What is Freenome funding to date?
Freenome has raised $1.35B to date.
Freenome major investors
Agent Capital
Ame Cloud Ventures
Andreessen Horowitz
Arrowmark Partners
Artis Ventures
Asset Management Ventures
Brightedge
Byers Capital
Catalio Capital Management
Crv
Dcvc
Ecor1 Capital
Farallon Capital Management
Fidelity Investments
Founders Fund
Gv
Innovation Endeavors
Intermountain Ventures
Janus Henderson Investors
K50 Ventures
Kaiser Permanente Ventures
Logos Capital
Longevity Vision Fund
Perceptive Advisors
Polaris Partners
Ra Capital Management
Ridgeback Capital
Roche Venture Fund
Rock Springs Capital
S28 Capital
S32
Sands Capital
Soleus Capital
Squarepoint Capital
Startx (Stanford-Startx Fund)
T. Rowe Price
Verily Life Sciences
Show All InvestorsShow Fewer Investors
Freenome pre-IPO valuation and funding rounds
Funding history chart
Funding round and deals details
Funding Date
Round
Amount Raised
Price per Share
Post-Money Valuation 3
Key Investors
02/15/2024
Series F
$263.96M
$7.40
$2.05B
Andreessen Horowitz, Ark Investments, Arrowmark Partners, Artis Ventures, Bain Capital, Brightedge Ventures, Cormorant Capital, Dcvc, Eventide Asset Management Llc, Intermountain Ventures, Perceptive Advisors, Polaris Partners, Pura Vida Investments, Quest Diagnostics, Ra Capital Management, Roche, Sands Capital, Section 32, Squarepoint Capital, T. Rowe Price Associates
Price per Share
$ xx.xx
Shares Outstanding
35,677,074
Liquidation Pref Order
1
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
6.0%
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
--
Key Investors
Andreessen Horowitz, Ark Investments, Arrowmark Partners, Artis Ventures, Bain Capital, Brightedge Ventures, Cormorant Capital, Dcvc, Eventide Asset Management Llc, Intermountain Ventures, Perceptive Advisors, Polaris Partners, Pura Vida Investments, Quest Diagnostics, Ra Capital Management, Roche, Sands Capital, Section 32, Squarepoint Capital, T. Rowe Price Associates
01/11/2022
Series E
$276.95M
$11.10
$2.74B
Roche
Price per Share
$ xx.xx
Shares Outstanding
24,942,143
Liquidation Pref Order
1
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
6.0%
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
--
Key Investors
Roche
12/07/2021
Series D
$299.25M
$7.52
$1.43B
Andreessen Horowitz, Artis Ventures, Bain Capital, Brightedge Ventures, Catalio Capital Management, Cormorant Capital, Dcvc, Farallon Capital Management, Fidelity, Gv, Janus Henderson Investors, Kaiser Permanente, Novartis, Perceptive Advisors, Polaris Partners, Ra Capital Management, Ridgeback Capital Management, Roche, Rock Springs Capital, Sands Capital, Section 32, Soleus Capital, T. Rowe Price Associates
Price per Share
$ xx.xx
Shares Outstanding
39,775,644
Liquidation Pref Order
1
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
6.0%
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
--
Key Investors
Andreessen Horowitz, Artis Ventures, Bain Capital, Brightedge Ventures, Catalio Capital Management, Cormorant Capital, Dcvc, Farallon Capital Management, Fidelity, Gv, Janus Henderson Investors, Kaiser Permanente, Novartis, Perceptive Advisors, Polaris Partners, Ra Capital Management, Ridgeback Capital Management, Roche, Rock Springs Capital, Sands Capital, Section 32, Soleus Capital, T. Rowe Price Associates
08/26/2020
Series C
$270M
$6.61
$927.08M
Andreessen Horowitz, Bain Capital, Brightedge, Catalio Capital Management, Colorectal Cancer Alliance, Cormorant Asset Management, Dcvc, Ecor1 Capital, Farallon Capital Management, Fidelity, Gv, Janus Henderson Investors, Kaiser Permanente, Novartis, Perceptive Advisors, Polaris Partners, Ra Capital Management, Roche, Rock Springs Capital, Sands Capital, Section 32, Soleus Capital, T. Rowe Price Associates
Price per Share
$ xx.xx
Shares Outstanding
40,826,799
Liquidation Pref Order
1
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
6.0%
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
--
Key Investors
Andreessen Horowitz, Bain Capital, Brightedge, Catalio Capital Management, Colorectal Cancer Alliance, Cormorant Asset Management, Dcvc, Ecor1 Capital, Farallon Capital Management, Fidelity, Gv, Janus Henderson Investors, Kaiser Permanente, Novartis, Perceptive Advisors, Polaris Partners, Ra Capital Management, Roche, Rock Springs Capital, Sands Capital, Section 32, Soleus Capital, T. Rowe Price Associates
07/24/2019
Series B
$165M
$4.56
$464.3M
Andreessen Horowitz, Brightedge Ventures, Dcvc, Gv, Kaiser Permanente, Perceptive Advisors, Polaris Partners, Ra Capital Management, Roche, Section 32, T. Rowe Price Associates, Verily Life Sciences
Price per Share
$ xx.xx
Shares Outstanding
36,207,457
Liquidation Pref Order
1
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
6.0%
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
--
Key Investors
Andreessen Horowitz, Brightedge Ventures, Dcvc, Gv, Kaiser Permanente, Perceptive Advisors, Polaris Partners, Ra Capital Management, Roche, Section 32, T. Rowe Price Associates, Verily Life Sciences
08/28/2017
Series A
$69.62M
$3.07
$196.16M
Allen & Company, Ame Cloud Ventures, Anne Wojcicki, Asset Management Ventures, Charles River Ventures, Dcvc, Founders Fund, Gv, Innovation Endeavors, Polaris Partners, Section 32, Spectrum 28
Price per Share
$ xx.xx
Shares Outstanding
22,660,320
Liquidation Pref Order
1
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
6.0%
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
--
Key Investors
Allen & Company, Ame Cloud Ventures, Anne Wojcicki, Asset Management Ventures, Charles River Ventures, Dcvc, Founders Fund, Gv, Innovation Endeavors, Polaris Partners, Section 32, Spectrum 28
06/19/2016
Series Seed-2
$5.55M
$0.61
$25.34M
Andreessen Horowitz, Dcvc, Founders Fund, Third Kind Venture Capital
Price per Share
$ xx.xx
Shares Outstanding
9,092,395
Liquidation Pref Order
1
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
6.0%
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
--
Key Investors
Andreessen Horowitz, Dcvc, Founders Fund, Third Kind Venture Capital
In early 2022, Freenome surpassed $1 billion in lifetime financing after raking in two nine-figure funding rounds barely a month apart, with plans to use the money to launch new studies of its cancer blood tests. Two years later, the company is adding to its coffers once again, with an eye toward both keeping those studies afloat and continuing to develop additional disease-detecting liquid biopsy tests. The latest funding round weighed in at $254 million, Freenome announced Thursday. It was led by Roche, which has participated in all of Freenome’s previous fundraising sessions and was also responsible for the $290 million contribution at the start of 2022 that brought Freenome’s total past the $1 billion mark.
Walgreens and biotech firm Freenome have announced a multi-year partnership to advance clinical studies of Freenome's blood-based tests for early cancer detection. Walgreens will use its national footprint and patient insights to engage diverse patient populations in Freenome's multi-cancer research program. The partnership will also work on building risk-prediction models and population health software to help identify people eligible for standard-of-care cancer detection testing.
Private companies exploring an IPO
See which private companies are preparing for the public market. Register to get full access to the latest secondary market pricing data.
Track trading activity and investor momentum across thousands of private companies. Register to view last matched prices and additional transactional details.
Forge, your trusted partner for pre-IPO insights and Freenome data
Forge is the trusted platform for buying and selling pre-IPO shares. Investors and shareholders worldwide rely on our deep data insights, liquidity solutions, and tailored investment opportunities to navigate the private market. Register to get started.
PLEASE READ THESE IMPORTANT LEGAL NOTICES & DISCLOSURES
Forge Price™ is a custom data-point calculated and disseminated by Forge Data LLC (“Forge Data”) and is a mark of Forge Data. Forge Price may rely on a very limited number of inputs in its calculation. Forge Price is prepared and disseminated solely for informational purposes. Redistribution is permitted solely with Forge’s written consent. While Forge has obtained information from sources it believes to be reliable, Forge does not perform an audit or undertake any duty of due diligence or independent verification of any information it receives. Forge does not guarantee the accuracy, completeness, timeliness, or availability of Forge Price, and are not responsible for any errors or omissions, regardless of the cause, or any results obtained from the use of Forge Price. Forge Price is derived from secondary activity on the Forge platform and other private market trading platforms, and other publicly-available datapoints collected by Forge. Forge Price is not intended to, and does not necessarily, represent the market price of any securities (I.e., the price at which you could buy or sell such securities). Neither reference to company names, nor calculation of Forge Price for a specific company, implies any affiliation between Forge and that company, any endorsement or sponsorship by Forge of any company or vice versa, or any partnership, joint venture or other commercial relationship between Forge and any company. Rights with respect to any company marks referred to herein are owned by the company. The dollar-figure and percentage displayed indicates the per share change in dollar amount and percentage since the most recent Forge Price change. Percentages are rounded to the nearest whole number.
Market activity indicates the level of activity for a company based on recent IOIs, secondary transactions, and pending transactions on Forge.
Post-Money Valuation represents the estimated valuation based on company-submitted Certificates of Incorporations (COIs).
Last Known Valuation represents a valuation gathered from non-COI, publicly available sources including company press releases or multiple concurring news articles.
Actively traded companies are companies with a high market activity with the highest post-money valuation in the same sector.
‘Stock Price’ or other private company metrics (‘PC Data’) may rely on a very limited number of trade and/or IOI inputs in their calculation. PC Data is prepared and disseminated solely for informational purposes. While Forge has obtained information from sources it believes to be reliable, Forge does not perform an audit or undertake any duty of due diligence or independent verification of any information it receives. Forge does not guarantee the accuracy, completeness, timeliness, or availability of PC Data, and are not responsible for any errors or omissions, regardless of the cause, or any results obtained from the use of PC Data. PC Data is derived from the performance and pricing of secondary activity on the Forge platform and other private market trading platforms. PC Data is not intended to, and does not necessarily, represent the market price of any securities (I.e., the price at which you could buy or sell such securities). Reference to company names does not imply any affiliation between Forge and that company, any endorsement or sponsorship by Forge of any company or vice versa, or any partnership, joint venture or other commercial relationship between Forge and any company. Rights with respect to any company marks referred to herein are owned by the company.
The news articles displayed on this page may be curated using artificial intelligence (AI) technology, which selects relevant content from a list of trusted web sources. While we strive for accuracy and reliability, the inclusion of an article does not imply endorsement or verification of its content. This communication is for informational purposes only. Investors should conduct their own research and consult a financial professional before making investment decisions.
Investing in private company securities is not suitable for all investors, is highly speculative, is high risk, and investors should be prepared to withstand a total loss of their investment. Private company securities are highly illiquid and there is no guarantee that a market will develop for such securities. Each investment carries its own risks, and investors should conduct their own due diligence regarding the investment, including obtaining independent professional advice. Past performance is not indicative of future results. This is not a recommendation, offer, solicitation of an offer, or advice to buy or sell securities by Forge, nor an offer of brokerage services in any jurisdiction where Forge is not permitted to offer brokerage services. Brokerage products and services are offered by Forge Securities LLC, a registered broker-dealer and member FINRA/SIPC. Please see other important disclaimers, disclosures and restrictions you acknowledge by using this website and to which you are subject.
August Private Market Update
